
    
      ACUITY is a phase 2a, monocentric, two-arm, randomised, double-blind, placebo-controlled
      study to evaluate the safety and tolerability of ACT-01 compared to placebo in patients with
      acute optic neuritis (AON) receiving the standard of care. Thirty-six eligible subjects aged
      18 to 60, with recent onset (visual loss symptoms) of unilateral AON (idiopathic or
      associated with multiple sclerosis) will be randomized to receive ACT-01 or placebo
    
  